

REMARKS

In the Office Action of March 27, 2007, the Examiner has required a supplemental election/restrictions. In particular, the Examiner has required an election of an inhibitor/activator and a single species/compound for each elected inhibitor/activator.

Applicants traverse this requirement. Reconsideration and withdrawal thereof are earnestly requested.

The Examiner believes that claim 23 is generic. In addition, the Examiner believes that the present application contains claims directed to more than one species of the generic invention and these species lack unity of invention because they are not so linked as to form a single general inventive concept under PCT Rule 13.1.

Applicants submit that the alleged species of inhibitor of adenylyl cyclase, an inhibitor of protein kinase A, an inhibitor of protein kinase C or an activator of Gi protein in claim 23, as divided by the Examiner at page 2 in the Office action, share the special technical feature of modulating cellular senescence and therefore, it is believed that unity of invention under PCT Rule is satisfied.

Applicants submit that there is not a serious burden placed upon the Examiner to search and consider all of the alleged species.

However, in order to be responsive to the outstanding single species election requirement, Applicants provisionally elect to prosecute an inhibitor of adenylyl cyclase and [9-(tetrahydro-2'-furyl) adenine]. It is believed that the elected species are readable upon all of the pending claims.

Accordingly, early examination on the merits is respectfully requested.

The Commissioner is hereby authorized to charge JHK Law's Deposit Account No. **502486** for such fees required under 37 CFR §§ 1.16 and 1.17 and to credit any overpayment to said Deposit Account No. **502486**.

April 24, 2007

Respectfully submitted,

/Joseph Hyosuk Kim/
Joseph Hyosuk Kim, Ph. D.
Registration No. 41,425

JHK Law
P.O. Box 1078
La Canada, CA 91012-1078
Telephone: 818-249-8177
Facsimile: 818-249-8277